Phase-2 Trials of the CAR-T reported complete remissions in 82% of patients, however, a concern was raised with the high incidence of the dangerous inflammatory condition – cytokine release syndrome
But what role does cord blood play?
Furthermore, they have found that the engineered NK cells taken from cord blood were actually more efficient at killing chronic lymphocytic leukaemia than NK cells taken from a patient’s own blood in CAR-T. The NK cells derived from cord-blood also do not need to be matched, eliminating the risk of graft vs. host disease.
Benefits of NK cells from cord blood:
- More efficient at killing leukaemia than cells from a patients own blood
- No matching requirements – eliminating the risk of graft vs. host disease
- Built in ‘suicide gene’ to shut down the cell if it triggers cytokine release syndrome
Request a Welcome Pack
Find out more about cord blood banking by downloading a Welcome Pack now.